Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed exchanges that its subsidiary, Optival Health Solutions Private Limited, received a 7-day suspension order for the drug license of a single store located at Devi Chowk, Rajamahendravaram in Andhra Pradesh. The order was issued by the Assistant Director, District Sales Licensing Authority, Drugs Control Administration, Rajamahendravaram, and received by the company on 31 October 2025. The action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940 and related Rules of 1945. The estimated potential revenue loss from this suspension is approximately Rs 1.75 lakhs. The suspension is limited to one store and the company has shared the details as required under SEBI's disclosure regulations.
The financial impact is negligible at around Rs 1.75 lakhs in potential revenue loss, involving just one store out of Medplus's large retail network. This is a routine compliance matter unlikely to materially affect the stock price or business operations.